Simplify Logo

Full-Time

Associate Scientist / Senior Associate Scientist

Platform Imaging

Posted on 8/8/2024

Generation Bio

Generation Bio

51-200 employees

Developing genetic medicines with non-viral delivery

Hardware
Biotechnology
Healthcare

Junior, Mid

Cambridge, MA, USA

Category
Bioinformatics
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Masters degree or a Bachelor’s with a minimum of 2 years related experience
  • Previous experience maintaining, propagating, seeding, transfecting, and preserving mammalian cell lines is required
  • Must be able to independently execute complex protocols with precision, consistency, and a mechanistic understanding of the steps
  • Experience with immunofluorescence, in situ hybridization, and/or other imaging preparations is highly desirable
  • Hands-on experience with fluorescence microscopy is a plus
  • Ability to support multiple projects across the platform
  • Ability to work in a highly collaborative, team-based environment
  • Organized, excellent communication skills, collaborative, team player mindset
  • Excellent written and verbal communication skills
Responsibilities
  • Plans and executes experiments, analyzes data and interprets results
  • Records findings in ELN (Benchling) and summarizes results in written and oral presentations
  • Prepares and images samples using a variety of novel and standard approaches
  • Performs qualitative and quantitative image analyses
  • Maintains awareness of relevant scientific advances in molecular imaging and pathology and suggests new approaches where appropriate
  • Contribute to improvement in the laboratory operational processes and establish standard operating protocols

Generation Bio

Company Stage

IPO

Total Funding

$536.4M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-23%

2 year growth

-20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.
INACTIVE